Proteros Appoints New Chief Financial Officer
News Oct 10, 2012
Arnd Christ has more than 12 years of international experience as a CFO in the biotechnology industry, with responsibilities in finance, operations, legal affairs and investor relations. He has successfully conducted a number of financial transactions and has a broad experience in all aspects of accounting and controlling.
Arnd Christ has a successful track record in various biotechnology companies and has most recently worked as Chief Financial Officer at MediGene AG, a listed biotechnology company in Germany. Formerly he served as CFO in biotechnology companies in Germany and Switzerland, as well as Finance Director within the Hoechst AG Group. Mr. Christ earned his master’s degree in Business Administration at Julius Maximilian University Würzburg.
"I am delighted to be joining such an accomplished management team that has built Proteros into a profitable business" commented Arnd Christ. "I am looking forward to helping the team execute on their growth strategy and in particular, the continued expansion into integrated lead discovery collaborations."
Dr. Torsten Neuefeind, Chief Executive Officer and founder of Proteros, stated: "We are very pleased to have Arnd join Proteros. His extensive international finance experience in Biotech as well as his solid CFO-background will be a valuable skill set to further support Proteros’ growth strategy in the collaborative research business and in higher value lead discovery partnerships."
Building Molecular Wires, One Atom at a TimeNews
Electronic devices are getting smaller and smaller. Early computers filled entire rooms. Today you can hold one in the palm of your hand. Now the field of molecular electronics is taking miniaturization to the next level. Researchers are creating electronic components so tiny they can’t be seen with the naked eye.READ MORE
Longevity Protein Reveals its SecretsNews
In a recent study, researchers revealed the three-dimensional structure of a proteins linked to longevity and metabolism, beta-Klotho, illuminating its intricate mechanism and therapeutic potential. The study findings could have implications for therapies developed to treat a wide range of medical conditions, including diabetes, obesity, and certain cancers.READ MORE